(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health has announced that the schizophrenia treatment it developed, which was later sold to Bristol Myers Squibb, has been approved by US regulators, triggering milestone payment and unlocking potential future royalties.
PureTech advanced its KarXT treatment through its own founded entity Karuna Therapeutics,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE